| Literature DB >> 34527322 |
Maria Elena Soto1,2, Eric Ochoa-Hein3, Javier E Anaya-Ayala4, Micaela Ayala-Picazo5, Solange Gabriela Koretzky6.
Abstract
BACKGROUND: Aortic aneurysm and dissection are important causes of morbimortality in patients with Marfan syndrome (MFS) and other connective tissue diseases that affect the cardiovascular tissues. Timely intervention through different surgical techniques improves the prognosis. Both sparing and replacement-type interventions of the aortic valve are used, but selection depends on the condition of the patient at the time of diagnosis, the patient's emergency condition, surgeon preference and hospital resources. Previous meta-analyses have suggested an advantage with the use of sparing-type interventions, but this finding must be updated and extended to patients with other connective tissue disorders. The objetive of this study is to evaluate the outcomes of valve-sparing root replacement versus aortic root replacement procedures in patients with MFS and similar connective tissue diseases that present with aortic aneurysm or dissection.Entities:
Keywords: Marfan syndrome (MFS); aortic aneurysm; aortic dissection; connective tissue disorders; surgical technique
Year: 2021 PMID: 34527322 PMCID: PMC8411183 DOI: 10.21037/jtd-21-789
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
CENTRAL search strategy
| No. | Strategy |
|---|---|
| #1 | MASS syndrome ALL FIELDS |
| #2 | SUPPLEMENTARY CONCEPT MASS syndrome |
| #3 | MESH DESCRIPTOR Ehlers-Danlos Syndrome |
| #4 | Ehlers-Danlos Syndrome ALL FIELDS |
| #5 | Ehlers Danlos Syndrome ALL FIELDS |
| #6 | EHLERS DANLOS disease ALL FIELDS |
| #7 | EHLERS-DANLOS disease ALL FIELDS |
| #8 | Loeys-Dietz Syndrome ALL FIELDS |
| #9 | Loeys Dietz Syndrome ALL FIELDS |
| #10 | Loeys-Dietz Aortic Aneurysm Syndrome ALL FIELDS |
| #11 | Loeys Dietz Aortic Aneurysm Syndrome ALL FIELDS |
| #12 | MESH DESCRIPTOR Loeys-Dietz Syndrome |
| #13 | Marchesani Syndrome ALL FIELDS |
| #14 | MESH DESCRIPTOR Weill-Marchesani Syndrome |
| #15 | Marchesani-Weill Syndromes ALL FIELDS |
| #16 | Marchesani-Weill Syndrome ALL FIELDS |
| #17 | Marchesani Weill Syndromes ALL FIELDS |
| #18 | Marchesani Weill Syndrome ALL FIELDS |
| #19 | Beals Hecht syndrome ALL FIELDS |
| #20 | Beals-Hecht syndrome ALL FIELDS |
| #21 | Shprintzen-Goldberg syndrome ALL FIELDS |
| #22 | Shprintzen Goldberg syndrome ALL FIELDS |
| #23 | Shprintzen-Goldberg Craniosynostosis Syndrome ALL FIELDS |
| #24 | Shprintzen Goldberg Craniosynostosis Syndrome ALL FIELDS |
| #25 | Shprintzen Golberg craniosynostosis ALL FIELDS |
| #26 | SUPPLEMENTARY CONCEPT Shprintzen Golberg craniosynostosis |
| #27 | MESH DESCRIPTOR Marfan Syndrome |
| #28 | MESH DESCRIPTOR Marfan Syndrome EXPLORE ALL TREES |
| #29 | marfan: TI,AB,KY |
| #30 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 |
| #31 | valve-sparing: ALL FIELDS |
| #32 | valve sparing: ALL FIELDS |
| #33 | bentall: ALL FIELDS |
| #34 | cvg: ALL FIELDS |
| #35 | david procedure: ALL FIELDS |
| #36 | aortic valve sparing: ALL FIELDS |
| #37 | aortic valve preserving: ALL FIELDS |
| #38 | aortic root replacement: ALL FIELDS |
| #39 | composite valve graft: ALL FIELDS |
| #40 | aortic root surgery: ALL FIELDS |
| #41 | Florida Sleeve: ALL FIELDS |
| #42 | #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 |
| #43 | Remodeling root repair: TI |
| #44 | Valve-sparing root replacement: TI |
| #45 | Root remodeling: TI |
| #46 | Valve-sparing reimplantation: TI |
| #47 | Aortic valve-sparing root replacement: TI |
| #48 | Valve configuration: TI |
| #49 | #43 OR #44 OR #45 OR #46 OR #47 OR #48 |
| #50 | aortic ring: TI |
| #51 | aortic valves: TI |
| #52 | Valve repair: TI |
| #52 | aortic regurgitation: TI |
| #54 | valves: TI |
| #55 | repair: TI |
| #56 | #50 OR #51 OR #52 OR #53 OR #54 OR #55 |
| #57 | #49 AND #56 |
| #58 | MESH DESCRIPTOR Cohort Studies |
| #59 | MESH DESCRIPTOR Cohort Studies EXPLORE ALL TREES |
| #60 | mid-term: ALL FIELDS |
| #61 | long-term: ALL FIELDS |
| #62 | cohort study: ALL FIELDS |
| #63 | cohort studies: ALL FIELDS |
| #64 | cohort: ALL FIELDS |
| #65 | #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 |
| #66 | #30 AND #42 AND #65 |
| #67 | #57 OR #66 |
| Filters | |
| Languages | Open |
| Article types | Open |
| Publication date | Open |
Figure 1PRISMA flow diagram: search and selection of literature.
Comparison of basal characteristics and outcome rates by type of surgical procedure
| Variable | Valve sparing procedure | Valve replacement procedure | P |
|---|---|---|---|
| Number of subjects | 1,807 | 2,218 | N/A |
| Number of studies | 33 | 26 | N/A |
| Age (years), mean ± SD | 33.3±3.3 | 35.8±7.3 | 0.0057 |
| Male, n (%) | 1,067/1,634 (65.3) | 843/1,262 (66.8) | 0.4201 |
| Emergency surgery, n (%) | 93/1,313 (7.1) | 307/1,606 (19.1) | <0.001 |
| Aortic diameter (cm), mean ± SD | 5.2±0.4 | 6.2±0.7 | 0.0232 |
| Dissection, n (%)* | 165/1,597 (10.3) | 749/1,943 (38.5) | <0.001 |
| Aneurysm, n (%)* | 1,181/1,262 (93.6) | 1,189/1,547 (76.9) | <0.001 |
| Person-years, median (IQR) | 129.5 (81.6–260.9) | 242.5 (51.5–680.2) | 0.61 |
| Rates per 10,000 person-years (median, IQR) | |||
| In-hospital mortality | 0 (0–0) | 0 (0–1.1) | 0.162 |
| Late mortality | 0.3 (0–2.8) | 2.3 (0–4.4) | 0.187 |
| Stroke | 0 (0–0.2) | 0.5 (0–1.1) | 0.084 |
| Acute myocardial infarction | 0 (0–0) | 0 (0–0.5) | 0.424 |
| Aortic insufficiency | 3.1 (1.3–6.3) | 0.4 (0–16.6) | 0.465 |
| Endocarditis | 0 (0–0) | 1.0 (0.3–3.6) | 0.002 |
| Thromboembolic events | 0 (0–0.2) | 1.5 (0.8–3.8) | 0.014 |
| Bleeding | 0.1 (0–1.9) | 2.2 (0.6–5.5) | 0.082 |
| Valve reintervention | 1.5 (0.1–6.3) | 0.8 (0–2.5) | 0.549 |
| Reoperation for bleeding | 3.0 (0.6–6.0) | 0.7 (0–2.4) | 0.303 |
| Aneurysm | 0.1 (0–0.5) | 1.0 (0.6–40.0) | 0.046 |
| Dissection | 0 (0–0.6) | 1.0 (0.5–1.8) | 0.126 |
| Arrhythmia | 1.2 (0.6–12.9) | 6.1 (1.1–32.2) | 0.436 |
| Survivors without stroke | 44.1 (35.0–70.0) | 25.5 (20.0–31.0) | ** |
| Survivors without acute myocardial infarction | 53.1 (43.8–89.0) | 25.5 (20.0–31.0) | ** |
| Survivors without aortic insufficiency | 57.7 (34.0–114.0) | 68.7 (38.3–99.1) | ** |
| Survivors without endocarditis | 79.0 (57.1–102.0) | 14.6 (12.2–16.7) | ** |
| Survivors without thromboembolic events | 152.7 (95.7–1596.8) | 26.7 (21.8–31.6) | ** |
| Survivors without bleeding | 77.5 (56.9–97.6) | 17.2 (13.4–26.8) | ** |
| Survivors without valve reintervention | 34.5 (25.6–86.3) | 38.9 (12.4–185.4) | 0.881 |
| Survivors without aneurysm | 53.1 (43.8–67.0) | 36.4 (24.2–468.0) | ** |
| Survivors without dissection | 43.8 (27.5–60.0) | 24.2 (18.1–30.3) | ** |
| Survivors without arrhythmia | 42.5 (38.2–46.9) | 846.6 (439.6–1,097.4) | ** |
*, the percentages of patients with dissection and aneurysm within groups do not add up to 100% because these categories are not mutually exclusive (i.e., patients could have had both conditions). Additionally, denominators are not similar because not all studies included both types of patients or did not make this distinction; **, no studies available for direct comparison of such outcomes between groups. N/A, not applicable; SD, standard deviation; IQR, interquartile range.
Summary of studies included in the meta-analysis
| Author | Country | Year | n | Mean follow-up (years) | Design | Reference |
|---|---|---|---|---|---|---|
| Bernhardt | Germany | 2011 | 88 | 3.2 | Retro | ( |
| Cameron | United States | 2009 | 372 | NR | Retro | ( |
| Coselli | United States | 2014 | 316 | 1 | Pro | ( |
| de Oliveira | Canada | 2003 | 105 | S=5.3, R=3.7 | Retro | ( |
| Gott | Multicentric | 1999 | 675 | NR | Pro | ( |
| Karck | Germany | 2004 | 119 | S=2.5, R=9.5 | Retro | ( |
| Moreau de Bellaing | France | 2019 | 15 | 6.8 | Retro | ( |
| Nicolò | Italy | 2017 | 59 | 8.1 | Retro | ( |
| Patel | United States | 2008 | 140 | NR | Retro | ( |
| Price | United States | 2016 | 165 | 17 | Retro | ( |
| Roubertie | France | 2009 | 15 | 7.4 | Retro | ( |
| Schoenhoff | Switzerland | 2015 | 59 | S=6.5, R=8.8 | Pro | ( |
| Sheick-Yousif | Israel | 2008 | 40 | S=4.4, R=2.1 | Retro | ( |
| Song | United States | 2014 | 200 | S=6.2, R=10.5 | Retro | ( |
| Volguina | Multicentric | 2009 | 151 | 0.1 | Pro | ( |
| Zehr | United States | 2004 | 83 | S=6.3, R=15 | Retro | ( |
NR, not reported; VS, valve sparing procedure; VR, valve replacement procedure; Retro, retrospective; Pro, prospective.
Figure 2Results of the meta-analysis for endocarditis and funnel plot. (A) Comparison of endocarditis between patients operated with valve sparing versus replacement surgical techniques. (B) Publication bias for endocarditis.
Figure 3Results of the meta-analysis for thomboembolic events and funnel plot. (A) Comparison of thromboembolic events between patients operated with valve sparing versus replacement surgical techniques. (B) Publication bias for thromboembolic events.
Figure 4Results of the meta-analysis for freedom from valve reintervention and funnel plot. (A) Comparison of freedom from valve reintervention between patients operated with the valve sparing versus replacement techniques. (B) Publication bias for freedom from valve reintervention.
Classification of evidence through the GRADE system
| Certainty assessment | No. of patients | Effect | Certainty | Importance | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Sparing | Replacement | Relative (95% CI) | Absolute (95% CI) | |||||||
| In-hospital mortality (follow-up: mean of 30 days) | |||||||||||||||||
| 7 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; all plausible residual confounding would suggest spurious effect, while no effect was observed; dose response gradient | 3/285 (1.1%) | 34/1,124 (3.0%) | RR 0.62 (0.22 to 1.74) | 1 fewer event per 100 (from 2 fewer to 2 more) | ⨁⨁⨁⨁ high | Important | |||||
| Late mortality (follow-up: mean of 10 years) | |||||||||||||||||
| 4 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; all plausible residual confounding would suggest spurious effect, while no effect was observed; dose response gradient | 6/395 (1.5%) | 8/164 (4.9%) | RR 0.35 (0.11 to 1.11) | 3 fewer events per 100 (from 4 fewer to 1 more) | ⨁⨁⨁⨁ high | Crítical | |||||
| Stroke (follow-up: mean of 10 years) | |||||||||||||||||
| 4 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; dose response gradient | 5/345 (1.4%) | 13/199 (6.5%) | RR 0.29 (0.11 to 0.75) | 5 fewer events per 100 (from 6 fewer to 2 fewer) | ⨁⨁⨁⨁ high | Crítical | |||||
| Aortic insufficiency (follow-up: mean of 8.5 years) | |||||||||||||||||
| 2 | Observational studies | Not serious | Not serious | Not serious | Not serious | Dose response gradient | 3/203 (1.5%) | 5/113 (4.4%) | RR 0.37 (0.09 to 1.52) | 3 fewer events per 100 (from 4 fewer to 2 more) | ⨁⨁⨁◯ moderate | Important | |||||
| Thromboembolism (follow-up: mean of 10 years) | |||||||||||||||||
| 2 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; dose response gradient. | 1/182 (0.5%) | 5/123 (4.1%) | RR 0.19 (0.03 to 1.13) | 3 fewer events per 100 (from 4 fewer to 1 more) | ⨁⨁⨁⨁ high | Crítical | |||||
| Valvular reintervention (follow-up: mean of 10 years) | |||||||||||||||||
| 5 | Observational studies | Not serious | Not serious | Not serious | Not serious | Very strong association; all plausible residual confounding would suggest spurious effect, while no effect was observed; dose response gradient | 21/493 (4.3%) | 8/231 (3.5%) | RR 0.79 (0.31 to 1.98) | 1 fewer event per 100 (from 2 fewer to 3 more) | ⨁⨁⨁⨁ high | Important | |||||
| Freedom from valvular reintervention (follow-up: mean of 10 years) | |||||||||||||||||
| 5 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; all plausible residual confounding would reduce the demonstrated effect; dose response gradient | 39/192 (20.3%) | 11/181 (6.1%) | RR 2.39 (1.24 to 4.60) | 8 more events per 100 (from 1 more to 22 more) | ⨁⨁⨁⨁ high | Crítical | |||||
| Endocarditis (follow-up: mean of 10 years) | |||||||||||||||||
| 3 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; dose response gradient | 1/395 (0.3%) | 7/174 (4.0%) | RR 0.14 (0.03 to 0.66) | 3 fewer events per 100 (from 4 fewer to 1 fewer) | ⨁⨁⨁⨁ high | Important | |||||
| Bleeding (follow-up: mean of 30 days) | |||||||||||||||||
| 4 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; dose response gradient | 6/345 (1.7%) | 7/199 (3.5%) | RR 0.51 (0.17 to 1.47) | 2 fewer events per 100 (from 3 fewer to 2 more) | ⨁⨁⨁⨁ high | Important | |||||
| Arrythmia (follow-up: mean of 10 years) | |||||||||||||||||
| 5 | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association; all plausible residual confounding would reduce the demonstrated effect; dose response gradient | 71/584 (12.2%) | 46/276 (16.7%) | RR 0.74 (0.52 to 1.04) | 4 fewer events per 100 (from 8 fewer to 1 more) | ⨁⨁⨁⨁ high | Not important | |||||
CI, confidence interval; RR, risk ratio.